sarscovinfect
patient
spontan
recov
without
clinic
intervent
small
percentag
succumb
diseas
character
tempor
chang
n
proteinspecif
glycoproteinspecif
neutral
antibodi
nab
respons
infect
patient
either
recov
succumb
sarscov
infect
recov
patient
found
higher
sustain
level
n
proteinspecif
glycoproteinspecif
nab
respons
suggest
antibodi
respons
like
play
import
role
determin
ultim
diseas
outcom
sarscovinfect
patient
sar
sever
acut
respiratori
syndrom
seriou
respiratori
ill
caus
novel
variant
coronaviru
sarsassoci
coronaviru
sarscov
holm
b
holm
enjuan
ksiazek
et
al
kuiken
et
al
lee
et
al
marra
et
al
peiri
et
al
b
poutanen
et
al
rota
et
al
tsang
et
al
sarscovinfect
patient
spontan
recov
without
clinic
intervent
small
percentag
succumb
diseas
age
one
major
factor
determin
fatal
rate
demonstr
significantli
higher
rate
patient
age
year
older
patient
younger
year
donnelli
et
al
role
immun
respons
howev
less
clear
systemat
evalu
cytotox
tcell
ctl
activ
infect
patient
report
show
detect
bind
antibodi
nucleocapsid
n
spike
glycoprotein
week
remain
detect
long
day
onset
symptom
shi
et
al
huang
et
al
leung
et
al
liu
et
al
nie
et
al
temperton
et
al
antibodi
isotyp
reactiv
n
protein
found
igm
igg
iga
although
kinet
differ
among
three
isotyp
viral
antigen
cours
diseas
shi
et
al
woo
et
al
c
also
report
patient
die
sar
produc
type
antibodi
n
protein
wherea
recov
infect
leung
et
al
howev
mani
studi
conduct
use
recombin
n
protein
produc
bacteria
e
coli
huang
et
al
li
et
al
leung
et
al
shi
et
al
shi
et
al
woo
et
al
c
conform
may
may
resembl
sarscov
particular
highli
glycosyl
protein
recent
studi
nie
et
al
temperton
et
al
use
pseudotyp
viru
bear
glycoprotein
viral
surfac
evalu
presenc
neutral
antibodi
nab
recov
individu
found
major
patient
detect
level
glycoproteinspecif
nab
last
day
onset
symptom
nie
et
al
temperton
et
al
studi
nie
et
al
known
remain
patient
never
develop
nab
simpli
infect
time
sampl
base
crosssect
studi
serum
sampl
collect
probabl
case
nie
et
al
found
nab
becam
detect
around
day
peak
around
day
could
sustain
well
day
onset
symptom
howev
nab
respons
unfortun
die
sarscov
infect
character
nie
et
al
report
use
elisabas
pseudotyp
retrovirusbas
neutral
system
character
tempor
chang
n
proteinspecif
antibodi
glycoproteinspecif
nab
respons
infect
patient
either
recov
succumb
sarscov
infect
found
recov
patient
antibodi
n
protein
detect
earli
day
peak
around
day
sustain
high
level
day
onset
symptom
howev
patient
die
n
proteinspecif
antibodi
either
never
develop
initi
develop
first
week
decreas
dramat
ensu
period
regard
glycoproteinspecif
nab
recov
deceas
patient
develop
detect
level
first
day
onset
symptom
although
actual
titer
significantli
lower
former
latter
group
product
nab
deceas
patient
surprisingli
faster
recov
patient
reach
highest
level
day
onset
symptom
nab
level
recov
patient
still
rise
set
two
group
patient
apart
subsequ
level
nab
ensu
period
infect
recov
patient
continu
higher
level
nab
peak
around
day
onset
symptom
deceas
patient
dramat
reduc
level
day
onset
symptom
result
suggest
high
sustain
level
n
proteinspecif
glycoproteinspecif
nab
correl
recoveri
sarscovinfect
patient
underli
mechan
signific
rapid
loss
antin
antibodi
anti
glycoprotein
nab
deceas
patient
current
unknown
could
either
due
exhaust
immun
system
result
excess
viru
replic
product
specif
loss
inhibit
antibodi
produc
cell
former
hypothesi
would
agre
immunopatholog
effect
sarscov
lung
spleen
rapid
gener
lymphopenia
sar
patient
acut
phase
infect
leung
et
al
nichol
et
al
peiri
et
al
b
poutanen
et
al
wong
et
al
woo
et
al
futur
studi
warrant
dissect
possibl
studi
nab
respons
sarscov
great
need
develop
sensit
specif
safe
assay
depend
function
glycoprotein
cultur
system
use
live
sarscov
explor
safeti
concern
technic
requir
perform
cultur
live
viru
hamper
broad
use
system
sought
overcom
technic
hurdl
develop
pseudotyp
retroviru
bear
nativ
fulllength
glycoprotein
sarscov
first
clone
wildtyp
fulllength
gene
pcr
amplif
directli
cdna
gener
fetal
rhesu
monkey
kidney
cell
infect
sarscov
genbank
access
number
zeng
et
al
improv
level
protein
express
also
construct
codonoptim
fulllength
gene
use
synthet
overlap
oligonucleotid
amplifi
product
clone
eukaryot
express
vector
control
cmv
promot
invitrogen
inc
carlsbad
ca
fulllength
gene
sequenc
confirm
sequenc
surpris
wildtyp
gene
express
detect
level
glycoprotein
despit
multipl
attempt
wherea
optim
gene
express
high
level
glycoprotein
transfect
cell
data
shown
suggest
genet
featur
wildtyp
gene
particular
promot
gene
combin
prevent
effici
transcript
translat
gene
construct
case
clear
optim
approach
significantli
increas
express
level
glycoprotein
mammalian
cell
critic
step
develop
pseudotyp
retroviru
system
therefor
use
codonoptim
gene
gener
pseudotyp
retroviru
specif
construct
contain
vprand
envdefect
provir
genom
express
plasmid
encod
optim
fulllength
glycoprotein
cotransfect
cell
gener
pseudotyp
retroviru
fig
control
plasmid
express
envelop
glycoprotein
jrfl
strain
also
cotransfect
construct
fortyeight
hr
transfect
cultur
supernant
collect
test
antigen
content
aalto
bio
reagent
dublin
ireland
standard
retroviru
input
subsequ
neutral
assay
test
entri
effici
pseudotyp
retroviru
bear
glycoprotein
multipl
cell
line
use
includ
vero
figur
demonstr
entri
effici
pseudotyp
retroviru
cell
line
clear
pseudotyp
retroviru
bear
glycoprotein
abl
enter
vero
effici
cell
tropism
pseudotyp
retroviru
therefor
consist
live
sarscov
report
previous
peiri
et
al
entri
effici
cell
line
cell
line
transduc
sarscov
receptor
gene
higher
suscept
cell
line
fig
hand
pseudotyp
retroviru
bear
jrfl
envelop
abl
infect
cell
line
consist
cellular
tropism
requir
express
entri
although
entri
effici
log
higher
compar
fig
confirm
entri
specif
sarscov
receptor
pseudotyp
retroviru
infect
three
suscept
cell
line
test
presenc
polyclon
antibodi
r
system
minneapoli
mn
solubl
ectodomain
protein
shown
figur
entri
pseudotyp
retroviru
bear
glycoprotein
three
cell
line
significantli
inhibit
presenc
antibodi
mgml
solubl
nm
suggest
retrovir
entri
mediat
specif
receptor
result
present
evid
pseudotyp
retroviru
capabl
infect
target
cell
line
suscept
live
sarscov
infect
nonsuscept
one
furthermor
infect
pseudotyp
retroviru
effect
block
polyclon
antibodi
specif
receptor
solubl
form
confirm
structur
function
integr
glycoprotein
pseudotyp
retroviru
result
complet
agreement
report
publish
previous
viral
pseudotyp
system
girogl
et
al
han
et
al
moor
et
al
nie
et
al
temperton
et
al
sinc
cell
line
suscept
entri
pseudotyp
retroviru
bear
glycoprotein
chose
cell
line
studi
neutral
antibodi
nab
activ
serum
sampl
collect
sarscovinfect
patient
crosssect
serum
sampl
collect
eight
deceas
eight
recov
patient
sarscov
infect
sequenti
serum
sampl
also
collect
three
deceas
three
recov
patient
studi
patient
admit
unit
christian
hospit
carita
medic
centr
march
april
studi
approv
local
ethic
committe
irb
rockefel
univers
diagnosi
coronaviru
infect
made
nasopharyng
swab
admiss
andor
convalesc
serum
day
onset
symptom
detail
report
clinic
manifest
patient
cours
infect
publish
elsewher
chu
et
al
first
studi
nab
activ
crosssect
sampl
serum
sampl
serial
dilut
prior
mix
normal
pseudotyp
retroviru
bear
glycoprotein
incub
hr
ad
cell
line
seventytwo
hr
later
cell
lyse
mlwell
cell
lysi
buffer
promega
madison
wi
min
rt
ml
lysat
test
luciferas
activ
figur
demonstr
serum
nab
activ
pseudotyp
retroviru
deceas
recov
b
group
deceas
group
nab
activ
detect
patient
though
signific
differ
exist
among
differ
patient
serum
sampl
patient
instanc
retain
neutral
activ
despit
dilut
fold
dilut
serum
sampl
howev
significantli
reduc
nab
activ
patient
fig
recov
group
nab
activ
also
detect
patient
variabl
level
four
eight
patient
dilut
minim
effect
serum
nab
activ
fold
dilut
reduc
nab
activ
rest
patient
fig
furthermor
compar
overal
nab
activ
deceas
recov
group
clear
trend
recov
group
rel
higher
level
compar
deceas
group
fig
although
none
comparison
given
dilut
yield
signific
differ
two
group
final
clear
dosedepend
nab
activ
sampl
test
reinforc
structur
function
integr
codonoptim
glycoprotein
surfac
pseudotyp
retroviru
fig
set
serum
sampl
also
test
antibodi
bind
activ
sarscov
n
protein
first
clone
fulllength
n
gene
bacteria
express
vector
novagen
inc
madison
wi
two
uniqu
restrict
enzym
site
nde
bamh
artifici
insert
end
gene
respect
end
n
gene
lack
termin
codon
fuse
histag
use
purifi
recombin
n
protein
e
coli
strain
novagen
inc
interact
ninta
agaros
qiagen
inc
valencia
ca
serum
antibodi
bind
activ
n
protein
evalu
quantit
elisa
figur
show
rel
titer
n
proteinspecif
bind
antibodi
deceas
recov
b
group
serum
sampl
antibodybind
activ
test
serial
dilut
signific
number
patient
group
detect
level
antin
bind
antibodi
found
although
larg
degre
variat
exist
among
differ
patient
overal
averag
level
bind
antibodi
recov
group
seem
higher
deceas
group
fig
four
patient
deceas
group
exampl
od
read
nm
less
dilut
one
patient
recov
group
fig
b
howev
none
comparison
given
dilut
reveal
statist
differ
two
group
suggest
bind
antibodi
n
protein
like
glycoproteinspecif
nab
activ
studi
may
associ
immunolog
surrog
diseas
outcom
sarscov
infect
lack
associ
level
antibodi
respons
glycoprotein
n
protein
diseas
outcom
could
due
insuffici
number
patient
studi
andor
actual
time
crosssect
sampl
sinc
antibodi
respons
protein
dynam
evolv
process
cours
infect
nie
et
al
shi
et
al
temperton
et
al
woo
et
al
studi
relationship
antibodi
respons
diseas
outcom
tempor
perspect
collect
sequenti
serum
sampl
three
deceas
three
recov
patient
sarscov
infect
four
seven
sequenti
sampl
collect
patient
day
day
deceas
patient
day
day
recov
patient
onset
symptom
serum
sampl
serial
dilut
mix
pseudotyp
retroviru
bear
glycoprotein
assay
nab
activ
figur
show
sequenti
serum
nab
activ
three
deceas
three
recov
patient
base
luciferas
activ
measur
hr
infect
pseudotyp
retroviru
three
deceas
patient
detect
level
nab
activ
day
rapidli
peak
reach
plateau
day
onset
symptom
fig
upper
panel
howev
dramat
drop
nab
activ
found
three
deceas
patient
approxim
day
afterward
coincid
clinic
deterior
fig
upper
panel
follow
death
day
onset
symptom
respect
chu
et
al
tempor
chang
nab
activ
recov
patient
distinctli
differ
deceas
patient
although
nab
activ
found
three
patient
day
onset
symptom
actual
titer
significantli
lower
compar
deceas
patient
time
period
p
particular
patient
fig
lower
panel
furthermor
took
averag
day
recov
patient
reach
peak
nab
activ
oppos
day
deceas
patient
fig
final
signific
reduct
nab
activ
peak
nab
activ
reach
one
patient
nab
activ
retain
highest
level
day
onset
symptom
data
shown
sequenti
antibodi
respons
n
protein
also
evalu
two
group
patient
shown
figur
three
deceas
patient
either
never
develop
antin
protein
antibodi
initi
develop
level
gradual
drop
day
onset
symptom
fig
upper
panel
recov
patient
howev
start
develop
antin
protein
antibodi
day
onset
symptom
gradual
increas
titer
least
compar
baselin
level
day
onset
symptom
fig
lower
panel
result
clearli
demonstr
strong
correl
strong
antibodi
respons
n
protein
surviv
sarscov
infect
patient
report
character
tempor
antibodi
respons
n
protein
glycoprotein
first
month
infect
sarscov
use
pseudotyp
retroviru
bear
glycoprotein
elisabas
method
compar
specif
nab
bind
antibodi
activ
crosssect
sequenti
sampl
collect
infect
patient
crosssect
studi
found
trend
recov
patient
tend
higher
level
nab
glycoprotein
bind
antibodi
n
protein
deceas
patient
trend
confirm
studi
sequenti
sampl
although
number
patient
studi
report
quit
small
consist
result
particularli
sequenti
studi
suggest
higher
level
antibodi
respons
correl
patient
recoveri
may
play
import
role
clear
remov
sarscov
infect
patient
interest
note
consider
differ
dynam
antibodi
respons
two
group
patient
nab
activ
deceas
patient
higher
develop
faster
compar
recov
patient
first
day
onset
symptom
activ
howev
lack
sustain
diminish
rapidli
ensu
period
infect
nab
activ
recov
patient
hand
develop
slowli
abl
maintain
high
level
extend
period
time
fact
mani
recov
patient
sustain
high
level
nab
activ
even
day
onset
symptom
taisheng
li
person
commun
mechan
underli
dichotomi
two
group
patient
current
unknown
possibl
excess
overlyquick
immun
activ
deceas
patient
trigger
systemat
breakdown
immun
system
sever
inflamm
signific
higher
level
proinflamm
cytokin
found
sar
patient
consist
hypothesi
lee
et
al
nichol
et
al
peiri
et
al
b
poutanen
et
al
tsang
et
al
wong
et
al
howev
systemat
breakdown
immun
system
could
also
direct
consequ
dysfunct
loss
function
bodili
system
respiratori
sinc
airspac
consolid
distinct
manifest
srar
patient
lee
et
al
nichol
et
al
peiri
et
al
b
poutanen
et
al
tsang
et
al
wong
et
al
splenic
astrophi
rapid
gener
lymphopenia
observ
sarscovinfect
patient
could
also
lead
reduc
level
antibodi
product
ksiazek
et
al
nichol
et
al
peiri
et
al
b
poutanen
et
al
wong
et
al
futur
studi
would
need
dissect
possibl
